Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 3/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | USP7 | Q93009 | 4/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194550 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL3193293 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL14403275 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL3193282 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL1751263 | 1.00 | RORC (0.56) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL2239870 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL953506 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL953505 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL2244835 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 | |
| SCHEMBL2240156 | 0.90 | TACR1 (0.61) | RORCTACR1GPR119USP7USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3890737-B1 | USP19 INHIBITORS FOR USE IN A METHOD OF TREATING OBESITY, INSULIN RESISTANCE AND TYPE II DIABETES | ALMAC DISCOVERY LTD (GB) | 2024-06-05 | — | — | EP | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| US-20220016115-A1 | USP19 INHIBITORS FOR USE IN THERAPY | ALMAC DISCOVERY LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| US-20210355106-A1 | NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2021-11-18 | — | — | US | disclosed |
| CN-109311888-B | Piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-09-14 | — | — | CN | disclosed |
| CN-113395965-A | USP19 inhibitors for treatment | 阿尔麦克探索有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-11046681-B2 | Substituted piperidines for the treatment of cancer | LES LABORATOIRES SERVIER (FR) | 2021-06-29 | — | — | US | disclosed |
| CN-113038990-A | Novel amino-pyrimidinone-piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-25 | — | — | CN | disclosed |
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-21 | — | — | US | disclosed |
| EP-3287441-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| EP-2336105-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8592454-B2 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | RORC 3261/4885TACR1 13/4885GPR119 197/4885 |
| US-20220016115-A1 | USP19 INHIBITORS FOR USE IN THERAPY | USP19, USP16, USP1 | RORC 3309/4885TACR1 4703/4885GPR119 29/4885 |
| US-20180170874-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC2, NPC1 | RORC 2485/4885TACR1 3078/4885GPR119 806/4885 |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | RORC 2651/4885TACR1 1028/4885GPR119 2066/4885 |
| US-20210355106-A1 | NEW AMINO-PYRIMIDONYL-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | QDPR, QARS1, QPCTL | RORC 2297/4885TACR1 386/4885GPR119 773/4885 |
| US-11046681-B2 | Substituted piperidines for the treatment of cancer | BCL2, MCL1, BCL2A1 | RORC 2869/4885TACR1 1186/4885GPR119 1462/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | RORC 2859/4885TACR1 9/4885GPR119 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.